COYA - CIK 0001835022
Coya Therapeutics, Inc. trades as COYA. In its fiscal 2025 annual report the company posted revenue of $7.95M, up 123.6% from the prior year and net income of -$21.23M. This page tracks Coya Therapeutics, Inc. through 222 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -133.1% to -267.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Annual report to shareholders | ARS | 2026-05-13 |
| Proxy materials | DEFA14A | 2026-05-13 |
| Proxy statement | DEF 14A | 2026-05-13 |
| Major company event | 8-K | 2026-05-12 |
| Prospectus supplement | 424B5 | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Insider trade | 4 | 2026-04-09 |
The largest companies sharing Coya Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Coya Therapeutics, Inc. reported revenue of $7.95M for fiscal year 2025, an increase of 123.6% year over year.
In its latest fiscal year Coya Therapeutics, Inc. reported a net loss of $21.23M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.